Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE Clinical trial

Despite increased cost due to taking a drug for prevention, dutasteride 0.5 mg/day may be cost effective in men at increased risk for PCa. </AbstractSection> Copyright Adis Data Information BV 2011

MoreLess

Year of publication:	2011
Authors:	Kattan, Michael ; Earnshaw, Stephanie ; McDade, Cheryl ; Black, Libby ; Andriole, Gerald
Published in:	Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 9.2011, 5, p. 305-315
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011000690